MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$52,165K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from financing-June Fin...
Proceeds from sales/maturities o...
Proceeds from at-the-market offe...
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-55,765
55,110
-25,175
-70,303
Change in fair value of convertible notes payable
-
-
0
21,584
Stock-based compensation
13,606
-3,208
4,295
6,318
Non-cash lease expense
25
-31
-17
74
Accretion/amortization on investments
358
319
174
-
Depreciation expense
9
-8
12
5
Prepaid expenses and other current assets
2,832
-7,215
413
1,358
Other assets
-
-
-
-88
Accounts payable
2,100
2,268
-4,878
4,938
Accrued expenses and other current liabilities
84
-1,668
4,578
2,862
Related party accrued expenses and other current liabilities
-495
-719
-332
-3,124
Operating lease liabilities
-30
-97
68
-
Net cash used in operating activities
-43,656
36,959
-22,124
-38,916
Purchases of investments
142,323
-74,694
148,592
-
Payment of security deposit
-
-
59
-
Purchases of property and equipment
-
-
57
136
Proceeds from sales/maturities of investments
44,691
65,428
-
-
Net cash used in investing activities
-97,632
140,374
-148,708
-136
Issuance costs offering-December PIPEFinancing
0
809
-
-
Issuance costs offering-October PIPEFinancing
0
31
-
-
Proceeds from financing-June Financing
162,073
-
-
-
Proceeds from at-the-market offerings, net of commissions-At The Market Offering
29,331
-
-
-
Proceeds from the pre-closing financing, net of 14,548 of offering costs
-
-
0
190,452
Proceeds from stock option exercises
1,534
45
-
-
Cash acquired in connection with the reverse recapitalization
-
-
0
156
Proceeds from espp issuances
585
-
-
-
Net cash provided by financing activities
193,523
-191,403
0
190,608
Effect of exchange rates on cash and cash equivalents
-70
-3
-4
-
Net increase in cash and cash equivalents
52,165
-14,073
-170,836
151,556
Cash and cash equivalents at beginning of period
50,106
50,106
69,386
-
Cash and cash equivalents at end of period
107,250
55,085
50,106
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
financing-June Financing
$162,073K
Proceeds from
at-the-market offerings, net...
$29,331K
Proceeds from stock
option exercises
$1,534K
Proceeds from espp
issuances
$585K
Net cash provided by
financing activities
$193,523K
(1.53%↑ Y/Y)
Net increase in cash
and cash...
$52,165K
(-65.58%↓ Y/Y)
Canceled cashflow
$141,358K
Proceeds from
sales/maturities of investments
$44,691K
Stock-based compensation
$13,606K
(115.35%↑ Y/Y)
Accounts payable
$2,100K
(-57.47%↓ Y/Y)
Accrued expenses and
other current...
$84K
(-97.06%↓ Y/Y)
Non-cash lease expense
$25K
(-66.22%↓ Y/Y)
Depreciation expense
$9K
(80.00%↑ Y/Y)
Net cash used in
investing activities
-$97,632K
(-71688.24%↓ Y/Y)
Net cash used in
operating activities
-$43,656K
(-12.18%↓ Y/Y)
Effect of exchange
rates on cash and cash...
-$70K
Canceled cashflow
$44,691K
Canceled cashflow
$15,824K
Purchases of investments
$142,323K
Net loss
-$55,765K
(20.68%↑ Y/Y)
Prepaid expenses and
other current assets
$2,832K
(108.54%↑ Y/Y)
Related party accrued
expenses and other...
-$495K
(84.15%↑ Y/Y)
Accretion/amortization on investments
$358K
Operating lease
liabilities
-$30K
Buy us a coffee
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)